PubMed Health⌕ Search

Biomedical subjects

H Wurzer

Publications and source records attributed to H Wurzer.

30 records · Page 2Linked to original sources
PubMed1992

[Effect of pirenzepine on motility of Oddi's sphincter].

Pirenzepine (Gastrozepin) has a proven positive effect in the treatment of peptic ulcers by blocking the so called muscarinic acetylcholine receptors of the gastric glands. Reports of positive results with pirenzepine in the treatment of acute pancreatitis led to new discussions about its biological effects. It is thought that there are three ways by which pirenzepine acts in the pancreas. It decreases enzymatic secretion and it increases the secretion of sodium bicarbonate and water. Furthermore, it is said to have a spasmolytic effect on the sphincter of Oddi. To prove this spasmolytic effect we performed endoscopic manometry at the sphincter of Oddi with intubation of the pancreatic duct in 12 healthy patients. After two minutes of manometric registration of the normal sphincter activity 6 patients received 10 mg pirenzepine i.v. while a control group of 6 patients received 2 ml of 0.9% NaCl i.v. During the next 5 minutes the basal pressure of the sphincter, the amplitude of concentrations, as well as their frequency and duration were monitored. There were no changes noticed in the placebo group. However, pirenzepine caused a considerable decrease of the 4 manometric parameters of the sphincter of Oddi in all patients. Within 5 minutes the basal tonus fell from 14.3 +/- 5.1 mm of mercury to 9.0 +/- 6.0 (p less than 0.01). The frequency of contractions dropped from 5.8 +/- 2.7 per minute to 2.0 +/- 2.1 (p less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Cholangiopancreatography, Endoscopic Retrograde↗
PubMed1991

[Dysfunction of the sphincter of Oddi as a cause of so-called postcholecystectomy syndrome].

In up to 30% of cases of the so-called postcholecystectomy syndrome functional disturbances of the sphincter of Oddi are responsible for the clinical picture. These pathological changes in pressure and motility at the sphincter can be identified by means of endoscopic manometry. We found dysfunction of the sphincter of Oddi in 4 out of 10 patients with so-called postcholecystectomy syndrome. In 2 patients in whom the basal pressure was higher than 40 mmHg endoscopic papillotomy was performed, after which the patients remained symptom-free. In one case tachyoddi was diagnosed and in another case the proportion of retrograde sphincter contractions exceeded 50%. Endoscopic manometry at the sphincter of Oddi enables many of the as yet unclarified postcholecystectomy symptoms to be identified.

Biliary Dyskinesia↗
PubMed1983

[Stapedius reflex. 1. Stapedius reflex threshold and recruitment].

UNLABELLED: The stapedius reflex threshold and pure tone threshold of 173 patients with normal hearing and cochlear disorders were examined (using Madsen ZO 73 equipment). CONCLUSIONS: 1. The aetiology of the cochlear hearing disorders does not influence the stapedial reflex threshold. 2. A linear regression between hearing loss and threshold difference was found in cochlear hearing disorders. 3. No correlation could be found between individual pure tone threshold and stapedial reflex threshold.

Adolescent↗
PubMed1983

[Stapedius reflex. 2. Latency periods of the stapedial reflex].

The reflex thresholds and initial latency times of the stapedial reflex of 50 patients with normal hearing and cochlear hearing loss were examined using Madson ZO 73 equipment. The following results were obtained: 1. The initial latency times of the stapedius reflex diminish proportional to the supra-threshold loudness. 2. No significant difference of the latency times was found between 0.5, 1, 2 and 4 kHz. 3. The initial latency times of patients with positive recruitment (cochlear hearing loss) do not differ from those of patients with normal hearing.

Auditory Threshold↗
PubMed1982

[Functional results in unilateral auditory canal atresia].

42 patients with unilateral congenital atresia of the ear were examined postoperatively. The results were as follows: 1. Tympanoplasty type III, stapes elevation by autologous ossicula, gave the best results on the average. 2. The discrimination tests gave poorer results than had been expected from the pure-tone threshold audiograms. 3. As a result of the operation, only one-third of the patients obtained a sense of hearing which made them fit for social contacts; hence, the indication for surgery should be examined critically before any action is taken.

Adolescent↗
PubMed1978

[Impedance measurements and otosclerosis (author's transl)].

Impedance measurements (model Madsen ZO 72) were performed on 158 patients with otosclerosis and compared with the operative findings. It was found that otosclerosis shows in 95% of the cases a symmetrical tympanogram, type A. Its amplitude does not differ from the standard values: that means that otosclerosis does not correlate with a flattened amplitude of the tympanogram. In addition there is no correlation between the intraoperative finding and the ampitude. The stapedius reflex could not be elicitated by acoustic stimuli.

Audiometry↗
PubMed1977

[Determination of the impaired ear's frequency selectivity using psychoacoustical tuning curves (author's transl)].

An apparatus for clinical use is described by which simplified psychoacoustical tuning curves can be measured near 500 Hz and near 4 kHz. Data produced by four groups (normal hearing, conductive hearing loss, noise induced hearing loss and degenerative hearing loss) are separately averaged and compared. The first mentioned two groups as well as the third in the low frequency range show good frequency resolution, the others, however, show largely decreased frequency resolution.

Audiometry↗
PubMedDate not supplied

A multicenter, randomized, double-blind comparison of roxatidine with ranitidine in the treatment of patients with uncomplicated benign gastric ulcer disease. The Multicenter Roxatidine Cooperative Study Group.

Roxatidine (150 mg, 312 patients) was compared with ranitidine (300 mg, 308 patients) in a randomized, double-blind, parallel-group, 6-week therapeutic study for the treatment of patients with uncomplicated, benign gastric ulcer disease. The study end points (verified by using endoscopy results) were fully healed ulcers at 4 or 6 weeks. The results of roxatidine therapy were comparable to those of ranitidine therapy: healing rates of 52% and 54% at week 4 and 77% and 76% at week 6 were recorded for roxatidine and ranitidine, respectively. The drugs produced comparable reductions in ulcer diameters and decreases in abdominal pain. Adverse events associated with both roxatidine (27%) and ranitidine (28%) were headache, diarrhea, and dizziness; rash was associated in 6 of 8 cases and in only 1 case with roxatidine. In this trial, roxatidine 150 mg once daily was as efficacious and safe as ranitidine 300 mg once daily for treatment of patients with uncomplicated, benign gastric ulcer disease.

Adult↗
PubMedDate not supplied

Efficacy and safety of pantoprazole in patients with gastroesophageal reflux disease using an intravenous-oral regimen. Austrian Intravenous Pantoprazole Study Group.

BACKGROUND/AIMS: To investigate the efficacy and safety of an intravenous-oral regimen using the gastric proton pump inhibitor pantoprazole. METHODOLOGY: Outpatients, with endoscopically diagnosed moderate or severe gastro-esophageal reflux disease (GERD stage II and III, respectively, Savary-Miller classification), were recruited from ten hospitals or private practice centers and enrolled into an open-labeled study (intention-to-treat population n=110, age 20-88 years; per-protocol population n=98). Patients were treated once daily with 40 mg pantoprazole which was administered as an intravenous injection for the initial 5-7 consecutive days, then as a tablet, for up to 8 weeks. The efficacy parameters were complete healing of lesions evaluated endoscopically after week 4 and 8, and relief from symptoms assessed after week 2 and 4. RESULTS: Complete healing was achieved in 85/98 (87%) and 93/98 (95%) per-protocol patients, after 4 and 8 weeks, respectively. The corresponding results for the intention-to-treat population were 85/110 (77%) and 93/110 (85%), respectively. After 2 weeks of treatment, heartburn, acid regurgitation, and pain on swallowing resolved in 97%, 98%, and 100% of the per-protocol patients, respectively. Faster healing was observed in non-smokers, those infected with Helicobacter pylori, and those with initial GERD stage II. The intravenous and oral administration phases were well tolerated. CONCLUSIONS: Pantoprazole (40 mg), applied as an intravenous-oral regimen to patients with GERD led to fast resolution of symptoms and high healing rates. For patients, temporarily unable to take oral medications, this regimen offers safe and reliable gastric acid suppression and allows the possibility of changing between the oral and intravenous administration without the need for dose adjustment.

2-Pyridinylmethylsulfinylbenzimidazoles↗
PubMedDate not supplied

Duodenal ulcer healing rates in a one-year follow-up study with ranitidine bismuth citrate and antibiotics.

BACKGROUND/AIMS: The aim of this study was to determine the one-year outcome of an eradication therapy with ranitidine bismuth citrate and antibiotics in Helicobacter pylori-positive duodenal ulcer patients in respect to ulcer and Helicobacter pylori relapse rates. METHODOLOGY: This multicenter, randomized, double-blind study involved 648 duodenal ulcer patients and had been carried out to compare the following regimens: ranitidine bismuth citrate b.i.d. co-prescribed with either clarithromycin 250 mg q.i.d. or clarithromycin 500 mg b.i.d. or clarithromycin 500 mg b.i.d. plus metronidazole 400 mg b.i.d. for 2 weeks, followed by a further 14 days of treatment with ranitidine bismuth citrate 400 mg b.i.d. to facilitate ulcer healing. H. pylori eradication was assessed by 13C-urea breath test and histology at least 4 weeks, 26 weeks and 52 weeks after the end of treatment. Ulcer relapse and H. pylori status were assessed 4 weeks, 26 weeks and 52 weeks post-treatment or if ulcer symptoms recurred. For the remainder of the follow-up period only serious adverse events were collected. RESULTS: At 12 months data of 438 (69%) patients were evaluable. The observed H. pylori eradication rates were 88-91%. H. pylori relapse rates were 2.1% after 26 weeks and 3.9% after 52 weeks. At the week 26 visit 26 patients (5.6%) and at the week 52 visit 25 patients (5.7%) had documented gastroesophageal reflux disease. CONCLUSIONS: Our data confirm the reduction of duodenal ulcer relapses after the cure of Helicobacter pylori infection.

Adolescent↗